With HPC Plans Pending, Microsoft Back-Burners Discovery for New Digital Pharma Initiative | GenomeWeb

Microsoft’s involvement in bioinformatics has been on the rise over the last few years, but it appears that the company is in no rush to enter the commercial discovery informatics market — even as it devotes more resources to downstream components of the pharmaceutical pipeline.

Last week, the desktop software giant launched its so-called Digital Pharma initiative, a “solutions framework” that relies on open standards, Web services, and products from Microsoft and its partner companies to help pharmaceutical firms collaborate and share information.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.